Ultraviolet Light Therapy for Systemic Lupus Erythematosus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004375|
Recruitment Status : Unknown
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was: Recruiting
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.
|Condition or disease||Intervention/treatment||Phase|
|Systemic Lupus Erythematosus||Procedure: ultraviolet A-1 light treatment||Phase 2|
Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Study Start Date :||September 1991|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004375
|United States, Louisiana|
|General Clinical Research Center and Charity Hospital (University of Louisiana)||Recruiting|
|New Orleans, Louisiana, United States, 70112-2822|
|Contact: Hugh McGrath, Jr. 504-568-4630 email@example.com|
|Alton Ochsner Medical Foundation Hospital||Recruiting|
|New Orleans, Louisiana, United States, 70121|
|Contact: Jawed Alam 504-842-3314|
|Study Chair:||Hugh McGrath, Jr.||Louisiana State University Health Sciences Center in New Orleans|